This webcast features: Corinne Branciaroli, Group Leader, CLD Viral Manufacturing, OXGENE, a WuXi Advanced Therapies Company. Lentiviral (LV) vectors have significant potential for cell and gene therapy applications. CAR-T and TCR therapies are becoming established treatments for blood malignancies that don’t respond to current therapies, and novel research aims to also exploit the usage of LV vectors to target solid tumors. However, challenges remain within the LV vector manufacturing process, such as achieving scalability and robustness. These challenges contribute to…
